MX2022000450A - Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos. - Google Patents

Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.

Info

Publication number
MX2022000450A
MX2022000450A MX2022000450A MX2022000450A MX2022000450A MX 2022000450 A MX2022000450 A MX 2022000450A MX 2022000450 A MX2022000450 A MX 2022000450A MX 2022000450 A MX2022000450 A MX 2022000450A MX 2022000450 A MX2022000450 A MX 2022000450A
Authority
MX
Mexico
Prior art keywords
therapeutic
targeting agents
peptide conjugates
microtubule targeting
microtubule
Prior art date
Application number
MX2022000450A
Other languages
English (en)
Spanish (es)
Inventor
Daniel Richard Marshall
Robert A Volkmann
Johanna Marie Csengery
Robert John Maguire
Original Assignee
Cybrexa 3 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cybrexa 3 Inc filed Critical Cybrexa 3 Inc
Publication of MX2022000450A publication Critical patent/MX2022000450A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/121,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2022000450A 2019-07-10 2020-07-09 Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos. MX2022000450A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962872638P 2019-07-10 2019-07-10
US202063041324P 2020-06-19 2020-06-19
PCT/US2020/041348 WO2021007402A1 (en) 2019-07-10 2020-07-09 Peptide conjugates of microtubule-targeting agents as therapeutics

Publications (1)

Publication Number Publication Date
MX2022000450A true MX2022000450A (es) 2022-04-25

Family

ID=71944331

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000450A MX2022000450A (es) 2019-07-10 2020-07-09 Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.

Country Status (19)

Country Link
US (2) US11555019B2 (enExample)
EP (1) EP3996749A1 (enExample)
JP (1) JP7675060B2 (enExample)
KR (1) KR20220051332A (enExample)
CN (1) CN114302744B (enExample)
AU (1) AU2020311925A1 (enExample)
BR (1) BR112022000297A2 (enExample)
CA (1) CA3146385A1 (enExample)
CL (1) CL2022000043A1 (enExample)
CO (1) CO2022001315A2 (enExample)
CR (1) CR20220057A (enExample)
EC (1) ECSP22010121A (enExample)
IL (1) IL289659B1 (enExample)
MX (1) MX2022000450A (enExample)
MY (1) MY209459A (enExample)
PE (1) PE20220485A1 (enExample)
PH (1) PH12022550037A1 (enExample)
TW (1) TW202116356A (enExample)
WO (1) WO2021007402A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
US11555019B2 (en) 2019-07-10 2023-01-17 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
CN116940691A (zh) 2021-01-08 2023-10-24 赛博克萨2公司 用于制备缀合物连接部分的方法
MX2024005938A (es) * 2021-11-17 2024-08-14 Cybrexa 4 Inc Conjugados peptídicos de inhibidores de tubulina peptídica como agentes terapéuticos.

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658920A (en) 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
EP0841924B1 (en) 1995-08-02 2002-10-02 Newcastle University Ventures Limited Benzimidazole compounds
DE69707860T2 (de) 1996-04-26 2002-04-11 Daiichi Pharmaceutical Co., Ltd. Verfahren zur herstellung von tetrahydroindolizinen
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
IN189180B (enExample) 1997-07-09 2003-01-04 Chong Kun Dang Corp
MY132496A (en) 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
EA003398B1 (ru) 1998-05-22 2003-04-24 Дайити Фармасьютикал Ко., Лтд. Лекарственный комплекс c полимерным носителем
CN1191093C (zh) 1998-10-30 2005-03-02 第一制药株式会社 Dds化合物及其测定方法
IL142917A0 (en) 1998-11-03 2002-04-21 Basf Ag Substituted 2-phenylbenzimidazoles, the production thereof and their use
US6495541B1 (en) 1999-01-11 2002-12-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6699876B2 (en) 1999-11-18 2004-03-02 Les Laboratoires Servier Camptothecin analogue compounds
CA2396513A1 (en) 1999-12-13 2001-06-14 Yanzhi Zhang Pseudomycin phosphate prodrugs
US6844318B2 (en) * 2000-03-15 2005-01-18 Bristol Myers Squibb Pharma Company Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
AU2001271037A1 (en) 2000-07-13 2002-01-30 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing dds compounds
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7771727B2 (en) 2002-03-01 2010-08-10 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
GEP20074230B (en) 2002-03-20 2007-11-12 Bristol Myers Squibb Co Phosphate prodrugs of fluorooxindoles
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CA2520997A1 (en) 2003-03-31 2004-10-14 Stacie Sara Canan-Koch Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
CN1816356A (zh) 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
MXPA05011811A (es) 2003-05-20 2006-02-17 Immunogen Inc Agentes citotoxicos mejorados que comprenden nuevos maitansinoides.
US7531530B2 (en) 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
PL2305221T3 (pl) 2003-12-01 2015-11-30 Kudos Pharm Ltd Inhibitory naprawy uszkodzeń DNA w leczeniu raka
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
PT1794163E (pt) 2004-09-22 2010-03-01 Pfizer Método para a preparação de inibidores de poli(adpribose)- polimerases
MX2007003314A (es) 2004-09-22 2007-08-06 Pfizer Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas.
ATE551345T1 (de) 2004-09-22 2012-04-15 Pfizer Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on
US8603483B2 (en) 2004-12-09 2013-12-10 Janssen Biotech, Inc. Anti-integrin immunoconjugates, methods and uses
WO2006078816A2 (en) 2005-01-18 2006-07-27 The Board Of Governors For Higher Education Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
ES2503719T3 (es) 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
KR20070120156A (ko) 2005-04-15 2007-12-21 이뮤노젠 아이엔씨 종양에서 이종 또는 혼성 세포 집단의 제거 방법
CA3000520C (en) 2005-08-24 2023-04-04 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
JP5227796B2 (ja) 2005-09-29 2013-07-03 アボット・ラボラトリーズ 2位においてフェニルによって置換された1h−ベンズイミダゾール−4−カルボキサミドは強力なparp阻害薬である
EP1945647B9 (en) 2005-11-08 2012-11-14 Immunogen, Inc. Processes for preparation of maytansinol
EP1976515A2 (en) 2006-01-17 2008-10-08 Abbott Laboratories Combination therapy with parp inhibitors
BRPI0710407A2 (pt) 2006-05-04 2012-04-17 Genentech Inc poliptìdeos, peixes-zebra transgênicos, modelos de sistemas, métodos de identificação de compostos, de identificação de agentes, métodos de tratamento de disfunções relativas a apoptose, método de identificação de agentes de prevenção ou redução da apoptose, composição de aumento da apoptose, composições de redução ou prevenção de apoptose, composição de apoptose, método de detecção, kits e artigo industrializado
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール
WO2008114114A2 (en) 2007-03-16 2008-09-25 Pfizer Products Inc. Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition
CN101784565B (zh) 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
PE20100083A1 (es) 2008-06-05 2010-02-17 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
SG10201810743WA (en) 2009-06-03 2018-12-28 Immunogen Inc Conjugation methods
WO2011066418A1 (en) 2009-11-25 2011-06-03 Academia Sinica The tumor-selective anti-cancer prodrug bqc-g
EP4166558A1 (en) 2010-02-12 2023-04-19 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
CA2790577A1 (en) 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
ES2584381T3 (es) 2010-05-05 2016-09-27 Prolynx Llc Liberación controlada de compuestos activos desde conjugados macromoleculares
EP4321168A3 (en) 2010-07-13 2024-04-24 Yale University, Inc. Environmentally sensitive compositions
AU2011289279B2 (en) 2010-08-13 2016-11-03 University Of Rhode Island Board Of Trustees Liposome compositions and methods of use thereof
AU2011323316B2 (en) 2010-11-03 2016-02-25 Immunogen, Inc. Cytotoxic agents comprising new ansamitocin derivatives
ME03353B (me) 2011-03-29 2019-10-20 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
MY171008A (en) 2011-03-29 2019-09-23 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
BR112014009050B1 (pt) 2011-10-14 2022-06-21 Medimmune Limited Conjugado anticorpo-fármaco de pirrolbenzodiazepinas, composição farmacêutica que compreende o mesmo, bem como compostos de pirrolbenzodiazepinas
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体-薬物コンジュゲート
EP2911701A4 (en) 2012-10-23 2016-06-08 Univ Johns Hopkins Novel self-assembling drug amphiphiles and methods for synthesis and application
US9919059B2 (en) 2012-12-10 2018-03-20 Massachusetts Institute Of Technology Multistage nanoparticle drug delivery system for the treatment of solid tumors
EP2927227A4 (en) 2013-01-03 2015-12-30 Celltrion Inc ANTIBODY CONCENTRATOR REMEDY CONJUGATE, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY TOGETHER THEREWITH
EP3566750A3 (en) 2013-02-28 2020-04-08 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
KR102442906B1 (ko) 2013-12-19 2022-09-14 씨젠 인크. 표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커
CN105917007A (zh) 2014-01-16 2016-08-31 克洛维斯肿瘤有限公司 Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗cd98抗体−薬物コンジュゲート
KR102445502B1 (ko) 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
EP3130608B1 (en) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
WO2016004043A1 (en) 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
AU2015305696B2 (en) 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib
JP6214790B2 (ja) 2014-09-16 2017-10-18 イース チャーム リミテッド 抗egfr抗体および同抗体の使用法
US10413615B2 (en) 2014-11-19 2019-09-17 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
KR102407261B1 (ko) 2015-02-27 2022-07-06 서울대학교산학협력단 나노 항암제형 및 그 제조 방법
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
US11160871B2 (en) * 2015-10-28 2021-11-02 Tarveda Therapeutics, Inc. SSTR-targeted conjugates and particles and formulations thereof
RS60237B1 (sr) 2015-11-24 2020-06-30 Theravance Biopharma R&D Ip Llc Prolekovi jak inhibitornih jedinjenja za lečenje gastorintestinalne inflamatorne bolesti
KR102498258B1 (ko) 2016-01-20 2023-02-10 삼성디스플레이 주식회사 표시 장치
US20170267727A1 (en) 2016-03-04 2017-09-21 Lehigh University Conjugates of pH Low Insertion Peptide and Monomethyl Auristatins in the Treatment of Solid Tumors
EP3426301A4 (en) 2016-03-08 2019-11-06 Los Gatos Pharmaceuticals, Inc. VERBUNDNANOPARTICLES AND USES THEREOF
EP3442592A4 (en) * 2016-04-13 2019-11-27 Tarveda Therapeutics, Inc. NEUROTENSIN RECEPTOR BINDING CONJUGATES AND FORMULATIONS THEREOF
GB201608885D0 (en) 2016-05-20 2016-07-06 Univ Birmingham Treatment
WO2017210608A1 (en) 2016-06-02 2017-12-07 Yale University Compositions and methods for targeting and treating homologous recombination-deficient tumors
EP3491007A4 (en) * 2016-07-29 2020-04-22 Memorial Sloan-Kettering Cancer Center RADIOACTIVELY MARKED LIGANDS FOR TARGETED PET / SPECT IMAGING AND METHOD FOR THE USE THEREOF
CA3032775C (en) 2016-08-16 2024-01-23 National Institute Of Advanced Industrial Science And Technology Malignant tumor target peptide
CA3037241A1 (en) * 2016-09-22 2018-03-29 Rhode Island Council On Postsecondary Education Fluorescent compound comprising a fluorophore conjugated to a ph-triggered polypeptide
CA3044898C (en) 2016-11-25 2022-04-05 Mabwell (shanghai) Bioscience Co., Ltd. Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof
WO2018118015A1 (en) 2016-12-19 2018-06-28 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
WO2018227132A1 (en) 2017-06-09 2018-12-13 Rhode Island Council On Postsecondary Education Linked and other ph-triggered compounds
CA3074208C (en) 2017-08-31 2023-10-03 Daiichi Sankyo Company, Limited Novel method for producing antibody-drug conjugate
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
MX2020007442A (es) 2018-01-12 2020-09-14 Prolynx Llc Protocolo para minimizar la toxicidad de dosificaciones de combinacion y agente formador de imagen para verificacion.
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
CN109232719B (zh) 2018-09-21 2021-06-29 中国科学院理化技术研究所 一种pH响应的抗菌肽及其制备方法和应用
EP3917528A4 (en) 2019-01-28 2022-12-28 University of Rhode Island Board of Trustees Phlip® targeted delivery of potent cytotoxic compounds
MX2021011812A (es) 2019-03-29 2021-10-22 Medimmune Ltd Compuestos y conjugados de estos.
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
US11555019B2 (en) 2019-07-10 2023-01-17 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
CN116940691A (zh) 2021-01-08 2023-10-24 赛博克萨2公司 用于制备缀合物连接部分的方法
CN117897175A (zh) 2021-04-29 2024-04-16 美商斯布雷克萨二号公司 拓扑异构酶i抑制剂的肽缀合物的给药方案
MX2024005938A (es) 2021-11-17 2024-08-14 Cybrexa 4 Inc Conjugados peptídicos de inhibidores de tubulina peptídica como agentes terapéuticos.

Also Published As

Publication number Publication date
KR20220051332A (ko) 2022-04-26
IL289659B1 (en) 2026-01-01
AU2020311925A1 (en) 2022-02-03
US12234212B2 (en) 2025-02-25
JP2022541747A (ja) 2022-09-27
JP7675060B2 (ja) 2025-05-12
US20210009536A1 (en) 2021-01-14
US11555019B2 (en) 2023-01-17
BR112022000297A2 (pt) 2022-03-15
ECSP22010121A (es) 2022-05-31
EP3996749A1 (en) 2022-05-18
CR20220057A (es) 2022-07-19
CL2022000043A1 (es) 2022-08-19
CN114302744A (zh) 2022-04-08
CO2022001315A2 (es) 2022-05-10
MY209459A (en) 2025-07-09
PE20220485A1 (es) 2022-04-04
PH12022550037A1 (en) 2023-04-12
TW202116356A (zh) 2021-05-01
CN114302744B (zh) 2025-08-26
US20240067616A1 (en) 2024-02-29
WO2021007402A1 (en) 2021-01-14
IL289659A (en) 2022-03-01
CA3146385A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
MX2022000449A (es) Conjugados peptídicos de citotoxinas como terapéuticos.
MX2022000450A (es) Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.
CY1123983T1 (el) Ειδικα σε axl συζευγματα αντισωματος-φαρμακου για τη θεραπεια καρκινου
CY1125358T1 (el) Θεραπεια συνδυασμου η οποια περιλαμβανει εναν mdm2 αναστολεα και εναν ή περισσοτερους επιπροσθετους φαρμακευτικως δραστικους παραγοντες για την αντιμετωπιση καρκινων
EA202190189A1 (ru) Сшитое производное димера пирролобензодиазепина (pbd) и его конъюгаты
EA202091134A1 (ru) Экзосомы для иммуноонкологической и противовоспалительной терапии
MX2019009255A (es) Proteínas quiméricas dirigidas y sus usos.
PH12018500693A1 (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
EA201790404A1 (ru) Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
MX381383B (es) Compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al receptor de asialoglicoproteina (asgpr)
PY1570443A (es) Anticuerpo drogas conjugados
MX2021011081A (es) Derivados de nicorandil.
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
PH12022550494A1 (en) Therapeutic conjugates
MX2017012102A (es) Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti.
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
SG11202011243XA (en) Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate
CO2024007413A2 (es) Conjugados peptídicos de inhibidores de tubulina peptídica como agentes terapéuticos
BR112022022590A2 (pt) Formulações farmacêuticas de acetato de abiraterona e niraparibe
EA202190541A1 (ru) НАЦЕЛЕННЫЕ НА NaPi2b КОНЪЮГАТЫ ПОЛИМЕР-АНТИТЕЛО ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2019089594A8 (en) Combination treatment with antibody-drug conjugates and cytarabine
AR133538A1 (es) Péptidos cíclicos dirigidos a fap y conjugados de los mismos
DOP2026000032A (es) Péptidos cíclicos dirigidos a fap y conjugados de los mismos
EP4247958A4 (en) TARGETING HOST-BACTERIAL INTERACTIONS TO TREAT MICROBIOTA-MEDIATED DISEASES
EA201992447A1 (ru) Конъюгаты кватернизированного ингибитора пути спасения никотинамидадениндинуклеотида